Evidence map›Paper›PMID 29921293›Full record

ArticleJournal of translational medicine2018

CHIP functions as an oncogene by promoting colorectal cancer metastasis via activation of MAPK and AKT signaling and suppression of E-cadherin.

Jingjing Xu, Jun Zhou, Hanjue Dai, Fei Liu, Wenjing Li, Wenjuan Wang, Feng Guo

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 53 citations in OpenAlex.

  1. CRISPR-Cas9 screening revealsMolecular therapy. Advances · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Chitosan degradation products promote healing of burn wounds of rat skin.Frontiers in bioengineering and biotechnology · 2022
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Jingjing XuCenter for Clinical Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Jun ZhouCenter for Clinical Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Hanjue DaiDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Fei LiuDepartment of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Wenjing LiDepartment of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Wenjuan WangState Key Laboratory of Microbial Technology, School of Life Sciences, Shandong University, Jinan, 250012, China.
Feng GuoDepartment of Oncology, Nanjing Medical University Affiliated Suzhou Hospital, Baita West Road 16, Suzhou, 215001, China. guofeng27@suda.edu.cn.
First Affiliated Hospital of Soochow University · CNNanjing Medical University · CNShandong University · CNSoochow University · CN

Funding

The National Natural Science Foundation of China 81400154The Natural Science Foundation of Jiangsu Provincial BK20151211The Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Youth Talent QNRC2016725
6 · The paper itself

Abstract

backgroundThe carboxyl terminus of Hsc70-interacting protein (CHIP) is an E3 ubiquitin ligase that plays a controversial role in different cancers, either as a tumor suppressor or a tumor promoter. To date, the exact function and underlying mechanism of CHIP in colorectal cancer (CRC) is not yet clear. Here we aimed to determine whether CHIP could affect the biological behaviors of CRC cells and its underlying mechanisms.

methodsStably transfected CHIP overexpression and depletion DLD-1 and HT-29 cells were established using Lipofectamine 2000. Cell growth was monitored by x-Celligence system. Cell proliferation was detected using CCK-8 and Brdu proliferation assay. Cell apoptosis and cell cycle were detected by flow cytometry analysis. Cell migration and invasion abilities were monitored by x-Celligence system, wound healing assay and transwell assay. In vivo intraperitoneal metastasis assay was performed to investigate the influence of CHIP on the tumor metastasis of CRC cells in nude mice. The expression of ERK, AKT, NF-кB signaling subunits and EMT related proteins were detected by Western blotting. The influence and function of CHIP on the protein expression of CRC cells were also elucidated by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. CRC microarray tissue was analyzed to investigate the CHIP expression and its clinical significance.

resultsCHIP depletion inhibited cell growth, migration and invasion potential of CRC cells, accompanied by downregulation of MAPK and AKT signaling activities and upregulation of E-cadherin. CHIP overexpression dramatically enhanced the migration and invasion abilities, due to the upregulation of MAPK and AKT signaling and downregulation of E-cadherin. The proteomic analysis confirmed that E-cadherin was decreased in CHIP-overexpressing CRC cells. Furthermore, clinical tissue data revealed that CHIP expression was upregulated in CRC samples and was significantly correlated with poor survival of CRC patients. Mechanically, CHIP probably activated the MAPK and AKT signaling, which inactivated GSK-3β. The GSK-3β inactivation, in turn, upregulated Slug and led to E-cadherin downregulation and EMT initiation.

conclusionsOur finding suggested that CHIP functions as an oncogene in the migration and metastasis of CRC, and is a potential unfavorable independent predictive biomarker for CRC. CHIP activates the AKT pathway to promote EMT and metastasis in CRC through the CHIP-MAPK/AKT-GSK-3β-Slug-E-cadherin pathways.

Indexed as

OncogenesAnimalsAntigens, CDCadherinsCell Line, TumorCell MovementCell ProliferationColorectal NeoplasmsEnzyme ActivationEpithelial-Mesenchymal TransitionFemaleGene SilencingGlycogen Synthase Kinase 3 betaHumansMaleMice, Inbred BALB CAntigens, CDCadherinsCDH1 protein, humanGlycogen Synthase Kinase 3 betaMitogen-Activated Protein KinasesProto-Oncogene Proteins c-aktSTUB1 protein, humanUbiquitin-Protein LigasesCHIPColorectal cancerEpithelial–mesenchymal transitionMetastasisOncogene

Identifiers

PMID29921293
PMCPMC6008917
OpenAlexW2808961121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.